Collectively these data demonstrate that IgA produced in the ovarian cancer microenvironment contributes to thwarting malignant progression through both antigen recognition, and via non-specific transcytosis through pIgR+ tumour cells. The gene discussed is CD79A; the disease is ovarian carcinoma.